ABBV
Bearish signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
AbbVie Inc.
- Nom
- AbbVie Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NYSE
- Capitalisation
- $499.5B
- Employés
- 57,000
- PDG
- Robert A. Michael
- Site web
- https://www.abbvie.com
- Marché
- AMGNAZNBMYGSKJNJLLY
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$8,177,500
Avg sell (VWAP, 90d window) $250.00 vs last close $286.74 (+14.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Liquidity
- Liquid $1,519,310,141/day · 20d vol
- Last synced
-
2026-10-27 02:37:16
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-14 | Donoghoe Nicholas | Sell · S | 32,710 | $250.00 | $8,177,500 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-14 | Pete Sessions | Sale | $15,001 - $50,000 |
| 2026-09-04 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-05-05 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2026-05-01 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2025-12-18 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-12-08 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-08-14 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-04 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-11 | Ritchie Torres | Sale (Full) | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-05-22 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-04-28 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2025-04-17 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2025-04-17 | Jefferson Shreve | Sale (Full) | $50,001 - $100,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-04-03 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-04-03 | Dwight Evans | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-01 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-03-17 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-02-25 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-02-24 | Jefferson Shreve | Purchase | $50,001 - $100,000 |
| 2025-01-24 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-12-06 | Virginia Ann Foxx | Purchase | $1,001 - $15,000 |
| 2024-11-20 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-26 | Ritchie Torres | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-07-02 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-04-10 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-23 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-12-08 | Michael C. Burgess | Sale (Full) | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-11-08 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-28 | Robert J. Wittman | Sale (Full) | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2023-09-06 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-30 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-14 | Michael C. Burgess | Sale (Full) | $15,001 - $50,000 |
| 2023-08-07 | Michael Guest | Purchase | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-07-28 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-27 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-07-14 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale (Full) | $50,001 - $100,000 |
| 2023-07-06 | Michael C. Burgess | Purchase | $15,001 - $50,000 |
| 2023-06-29 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-06-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-26 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-05-26 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-05-19 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-28 | Kathy E. Manning | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-28 | Kathy E. Manning | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-17 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-04-10 | Daniel Goldman | Sale | $15,001 - $50,000 |
| 2023-04-10 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-03-24 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-03-07 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-02-21 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-07 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-31 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-01-27 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-20 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-12 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-08-05 | Dwight Evans | Purchase | $1,001 - $15,000 |
| 2022-07-27 | Kathy E. Manning | Sale | $1,001 - $15,000 |
| 2022-07-27 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2020-11-16 | Rick Allen | Purchase | $15,001 - $50,000 |
| 2020-05-12 | Rick Allen | Purchase | $15,001 - $50,000 |
Signal
Bearish signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
AbbVie's catalyst score of 70 reflects a genuine near-term event setup (SKYRIZI FDA approval + Q3 earnings), but the severely stressed balance sheet — negative equity, current ratio below 0.7, and debt-to-capital above…
The first sentence of the analysis written for ABBV on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 0.67 · operating margin 33% — readings disagree
Suggested stop 261.09, nearest stored support minus 0.5 ATR(8.9% under the last close). Reward/risk to the next stored resistance is 0.18. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-26 How Do You Tell a Yield Trap From a Real $6,400-a-Month Dividend Portfolio? A 10% yield sounds like it solves the $6,400 monthly target with far less capital, but two of the three tests that expose a yield trap can disqualify a holding before you ever collect a check.
- 2026-10-26 AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30 AbbVie (NYSE:ABBV | ABBV Price Prediction) reports third-quarter results before the open on October 30. Shares are up 28.55% year to date, and options pricing implies a roughly 5% move on the release.
- 2026-10-26 3,545 AbbVie Inc. $ABBV Shares Purchased by IRON Financial LLC IRON Financial LLC raised its position in AbbVie Inc. (NYSE: ABBV) by 122.4% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 6,441 shares of the company''s stock after purchasing an additional 3,545 shares during the period. IRON Financial LLC''s holdings in AbbVie were worth
- 2026-10-26 Best Dividend Kings: October 2026 Dividend Kings have outperformed SPY YTD, rising 13.5% versus SPY''s 12.32%, with a strong October rebound. Twenty-six Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of at least 10%. Dividend growth for the Kings in 2026 averages 4.65%, with recent increases from GRC, NWN, and RPM.
- 2026-10-26 Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy Despite its high price relative to earnings, AbbVie remains an attractive stock.
- 2026-10-25 A Worthwhile Exit Strategy This week could mark something that hasn''t happened to me in years—I may end up selling my shares of AbbVie (ABBV) at a price below the market value. It''s all going to depend on if the share price ends the week above $280.
- 2026-10-25 AbbVie Inc. $ABBV Stock: Evergreen Capital Management LLC Grows Stake Evergreen Capital Management LLC lifted its position in shares of AbbVie Inc. (NYSE: ABBV) by 11.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,672 shares of the company''s stock after acquiring an additional 5,756 shares during the
- 2026-10-23 U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie''s SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn''s Disease U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie''s SKYRIZIÂ (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn''s DiseasePR News
- 2026-10-23 U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie''s SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn''s Disease Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni and endoscopic responseii at week 12 compared with placebo in patients with Crohn''s disease; results were particularly strong in patients without prior advanced therapy failureiii The safety profile of subcutaneous induction was generally consistent with the established SKYRIZI profile in Crohn''s disease, with no new safety risks identified FDA also approved an update to the U.S. Prescribing Information warning and precautions across all indications to allow healthcare providers to use clinical judgment when determining whether tuberculosis (TB) testing is needed NORTH CHICAGO, Ill., Oct. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn''s disease (CD)iv.
- 2026-10-23 AbbVie''s Dividend Survived Humira''s Patent Cliff. Will Merck and Amgen''s? When a drugmaker''s top product loses patent protection, the dividend usually takes the hit.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% | |
| Ebit Margin | 15.5% | 11.6% | 15.6% | 27.1% | 27.4% | |
| Ebitda Margin | 28.8% | 26.5% | 31.6% | 41.6% | 42.6% | |
| Operating Profit Margin | 32.8% | 16.2% | 23.5% | 31.2% | 31.9% | |
| Pretax Profit Margin | 10.8% | 6.6% | 11.5% | 23.2% | 23.1% | |
| Continuous Operations Profit Margin | 6.9% | 7.6% | 9.0% | 20.4% | 20.6% | |
| Net Profit Margin | 6.9% | 7.6% | 9.0% | 20.4% | 20.5% | |
| Bottom Line Profit Margin | 6.9% | 7.5% | 8.9% | 20.3% | 20.4% | |
| Current Ratio | 0.671 | 0.660 | 0.872 | 0.964 | 0.794 | |
| Quick Ratio | 0.557 | 0.552 | 0.764 | 0.842 | 0.705 | |
| Solvency Ratio | 0.090 | 0.096 | 0.109 | 0.167 | 0.153 | |
| Cash Ratio | 0.121 | 0.143 | 0.339 | 0.311 | 0.277 | |
| Price To Earnings Ratio | 96.409 | 74.042 | 56.766 | 24.302 | 20.895 | |
| Price To Earnings Growth Ratio | -77.127 | -6.125 | -0.963 | 9.263 | 0.152 | |
| Forward Price To Earnings Growth Ratio | -77.127 | -6.125 | -0.963 | 9.263 | 0.152 | |
| Price To Earnings Diluted Ratio | 96.409 | 74.351 | 56.974 | 24.376 | 20.992 | |
| Price To Earnings Diluted Growth Ratio | -115.209 | -6.128 | -0.966 | 8.735 | 0.153 | |
| Price To Book Ratio | -123.958 | 94.542 | 26.447 | 16.588 | 15.554 | |
| Price To Sales Ratio | 6.628 | 5.580 | 5.044 | 4.930 | 4.265 | |
| Price To Free Cash Flow Ratio | 22.752 | 17.628 | 12.419 | 11.804 | 10.898 | |
| Price To Operating Cash Flow Ratio | 21.300 | 16.715 | 11.996 | 11.475 | 10.522 | |
| Debt To Assets Ratio | 0.516 | 0.502 | 0.446 | 0.462 | 0.529 | |
| Debt To Equity Ratio | -21.122 | 20.403 | 5.803 | 3.720 | 5.035 | |
| Debt To Capital Ratio | 1.050 | 0.953 | 0.853 | 0.788 | 0.834 | |
| Long Term Debt To Capital Ratio | 1.058 | 0.948 | 0.834 | 0.774 | 0.806 | |
| Financial Leverage Ratio | -40.966 | 40.650 | 13.003 | 8.045 | 9.510 | |
| Working Capital Turnover Ratio | -4.465 | -6.257 | -18.369 | -13.920 | -9.562 | |
| Operating Cash Flow Ratio | 0.440 | 0.485 | 0.604 | 0.844 | 0.647 | |
| Operating Cash Flow Sales Ratio | 0.311 | 0.334 | 0.420 | 0.430 | 0.405 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.936 | 0.948 | 0.966 | 0.972 | 0.965 | |
| Debt Service Coverage Ratio | 1.311 | 1.610 | 1.678 | 3.451 | 1.490 | |
| Interest Coverage Ratio | 6.945 | 3.254 | 5.736 | 8.124 | 7.397 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.175 | 2.764 | 3.176 | 5.798 | 1.797 | |
| Operating Cash Flow Coverage Ratio | 0.276 | 0.277 | 0.380 | 0.389 | 0.294 | |
| Capital Expenditure Coverage Ratio | 15.675 | 19.308 | 29.394 | 35.889 | 28.942 | |
| Dividend Paid And Capex Coverage Ratio | 1.479 | 1.567 | 2.018 | 2.323 | 2.267 | |
| Dividend Payout Ratio | 2.758 | 2.577 | 2.167 | 0.849 | 0.802 | |
| Enterprise Value Multiple | 26.614 | 25.263 | 18.710 | 14.114 | 12.848 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 70.2% | ▲0.2% | ▲1.9% |
| Ebit Margin | 15.5% | ▲3.9% | ▼-3.9% |
| Ebitda Margin | 28.8% | ▲2.4% | ▼-5.4% |
| Operating Profit Margin | 32.9% | ▲16.6% | ▲5.7% |
| Pretax Profit Margin | 10.8% | ▲4.2% | ▼-4.3% |
| Continuous Operations Profit Margin | 6.9% | ▼-0.7% | ▼-6.0% |
| Net Profit Margin | 6.9% | ▼-0.7% | ▼-6.0% |
| Bottom Line Profit Margin | 6.9% | ▼-0.7% | ▼-5.9% |
| Current Ratio | 0.671 | ▲0.011 | ▼-0.121 |
| Quick Ratio | 0.557 | ▲0.005 | ▼-0.127 |
| Solvency Ratio | 0.090 | ▼-0.006 | ▼-0.033 |
| Cash Ratio | 0.121 | ▼-0.022 | ▼-0.117 |
| Price To Earnings Ratio | 96.409 | ▲22.368 | ▲41.926 |
| Price To Earnings Growth Ratio | -77.127 | ▼-71.002 | ▼-62.167 |
| Forward Price To Earnings Growth Ratio | -77.127 | ▼-71.002 | ▼-62.167 |
| Price To Earnings Diluted Ratio | 96.409 | ▲22.058 | ▲41.789 |
| Price To Earnings Diluted Growth Ratio | -115.209 | ▼-109.081 | ▼-92.526 |
| Price To Book Ratio | -123.958 | ▼-218.499 | ▼-129.792 |
| Price To Sales Ratio | 6.628 | ▲1.047 | ▲1.338 |
| Price To Free Cash Flow Ratio | 22.752 | ▲5.123 | ▲7.651 |
| Price To Operating Cash Flow Ratio | 21.300 | ▲4.585 | ▲6.898 |
| Debt To Assets Ratio | 0.516 | ▲0.014 | ▲0.025 |
| Debt To Equity Ratio | -21.122 | ▼-41.525 | ▼-23.890 |
| Debt To Capital Ratio | 1.050 | ▲0.096 | ▲0.154 |
| Long Term Debt To Capital Ratio | 1.058 | ▲0.110 | ▲0.174 |
| Financial Leverage Ratio | -40.966 | ▼-81.616 | ▼-47.015 |
| Working Capital Turnover Ratio | -4.465 | ▲1.792 | ▲6.050 |
| Operating Cash Flow Ratio | 0.440 | ▼-0.046 | ▼-0.164 |
| Operating Cash Flow Sales Ratio | 0.311 | ▼-0.023 | ▼-0.069 |
| Free Cash Flow Operating Cash Flow Ratio | 0.936 | ▼-0.012 | ▼-0.021 |
| Debt Service Coverage Ratio | 1.311 | ▼-0.299 | ▼-0.597 |
| Interest Coverage Ratio | 6.945 | ▲3.691 | ▲0.653 |
| Short Term Operating Cash Flow Coverage Ratio | 2.175 | ▼-0.589 | ▼-0.967 |
| Operating Cash Flow Coverage Ratio | 0.276 | ▼-0.002 | ▼-0.047 |
| Capital Expenditure Coverage Ratio | 15.675 | ▼-3.633 | ▼-10.166 |
| Dividend Paid And Capex Coverage Ratio | 1.478 | ▼-0.089 | ▼-0.452 |
| Dividend Payout Ratio | 2.758 | ▲0.181 | ▲0.928 |
| Enterprise Value Multiple | 26.614 | ▲1.351 | ▲7.104 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $405.34B | $314.35B | $273.99B | $286.21B | $239.66B | |
| Enterprise value | $469.18B | $376.67B | $321.29B | $341.20B | $307.49B | |
| EV / Sales | 7.67x | 6.69x | 5.92x | 5.88x | 5.47x | |
| EV / Op. cash flow | 24.66x | 20.03x | 14.07x | 13.68x | 13.50x | |
| EV / Free cash flow | 26.34x | 21.12x | 14.56x | 14.07x | 13.98x | |
| EV / EBITDA | 26.61x | 25.26x | 18.71x | 14.11x | 12.85x | |
| Net debt / EBITDA | 3.62x | 4.18x | 2.75x | 2.27x | 2.83x | |
| Current ratio | 0.67x | 0.66x | 0.87x | 0.96x | 0.79x | |
| Income quality | 4.50x | 4.39x | 4.74x | 2.11x | 1.97x | |
| Graham number | — | $10 | $19 | $38 | $36 | |
| Graham net-net | -$68 | -$66 | -$57 | -$58 | -$63 | |
| Tax burden | 64.1% | 115.1% | 77.8% | 87.8% | 88.9% | |
| Interest burden | 69.5% | 57.0% | 73.8% | 85.8% | 84.3% | |
| Working capital | -$14.23B | -$13.17B | -$4.84B | -$1.07B | -$7.27B | |
| Invested capital | $80.42B | $86.99B | $88.05B | $103.45B | $106.17B | |
| Return on assets | 3.2% | 3.2% | 3.6% | 8.5% | 7.9% | |
| Operating ROA | 14.9% | 6.8% | 9.3% | 12.7% | 12.1% | |
| Return on tangible assets | 9.3% | 10.7% | 10.4% | 30.2% | 30.2% | |
| Return on equity | -129.2% | 128.7% | 46.9% | 68.6% | 74.9% | |
| Return on invested capital | 13.0% | 8.9% | 9.6% | 14.0% | 12.9% | |
| Return on capital employed | 22.2% | 9.5% | 13.2% | 16.6% | 16.1% | |
| Earnings yield | 1.0% | 1.4% | 1.8% | 4.1% | 4.8% | |
| Free cash flow yield | 4.4% | 5.7% | 8.1% | 8.5% | 9.2% | |
| Capex / Op. cash flow | 6.4% | 5.2% | 3.4% | 2.8% | 3.5% | |
| Capex / Depreciation | 14.9% | 11.6% | 8.9% | 8.2% | 9.2% | |
| Capex / Sales | 2.0% | 1.7% | 1.4% | 1.2% | 1.4% | |
| SG&A / Sales | 22.9% | 26.2% | 23.7% | 26.3% | 22.0% | |
| R&D / Sales | 14.9% | 22.7% | 14.1% | 11.2% | 14.3% | |
| Stock comp / Sales | 1.6% | 1.6% | 1.4% | 1.2% | 1.2% | |
| Intangibles / Total assets | 65.9% | 70.3% | 65.3% | 71.8% | 73.9% | |
| Days sales outstanding | 75d | 71d | 75d | 71d | 65d | |
| Days payables outstanding | 72d | 64d | 66d | 61d | 60d | |
| Operating cycle | 174d | 161d | 148d | 146d | 130d | |
| Cash conversion cycle | 102d | 97d | 82d | 84d | 70d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years